GleamWall
中文EN

ERNA Ernexa Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 748592 · Fiscal year ends 12/31

Financial factors as of 2024-12-31 (2024Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY755.9%
TTM net income YoY-105.6%
TTM EPS YoY-1,100.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin83.5%
Operating margin-2,693.1%
Net margin-7,652.7%
FCF margin-2,784.4%
EBITDA margin-2,648.8%

Returns

ROE-2,264.3%
ROA-163.7%
ROIC (approx.)—
Asset turnover0.02x

Leverage & solvency

Liabilities / assets67.7%
Debt / equity0.00x
Current ratio0.80x
Interest coverage2.09x

Cash quality & payout

Operating cash flow / net income0.36x
Accruals ratio-105.5%
Payout ratio—
Capex / revenue63.4%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue—$582,000
Cost of revenue—$96,000
Gross profit—$486,000
R&D expense$4.16M$4.60M
SG&A expense$5.16M$13.13M
Operating income-$9.32M-$15.67M
Interest expense-$100,000-$6.80M
Pretax income-$14.13M-$44.51M
Income tax-$45,000$30,000
Net income-$14.08M-$44.54M
EBITDA-$9.25M-$15.54M
EPS (basic)-2.24-48.96
EPS (diluted)-2.24-48.96
Weighted avg. shares (diluted)6.31M910,000
Balance sheet
Cash & equivalents$1.88M$1.73M
Current assets$3.13M$2.35M
PP&E, net$94,000$85,000
Goodwill$2.04M$2.04M
Total assets$5.83M$5.27M
Current liabilities$3.11M$2.94M
Total liabilities$3.43M$3.57M
Shareholders' equity$2.40M$1.70M
Shares outstanding314,0003.43M
Cash flow statement
Operating cash flow-$7.02M-$15.84M
Capital expenditure$37,000$369,000
Free cash flow-$7.05M-$16.20M
Investing cash flow-$37,000-$365,000
Financing cash flow$7.21M$6.26M
Depreciation & amortization$65,000$139,000
Stock-based compensation$1.50M$1.52M

Free plan shows the latest 2 periods; Pro shows all 16 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.